• Heidi Ledford
• 12 Sep, 2019

Many experimental cancer drugs might be succeeding in unintended ways, finds a study that used CRISPR–Cas9 gene editing to investigate how such drugs interact with malignant cells. An analysis of ten drugs — including seven now in clinical trials — found that the proteins they target are not crucial for the survival of cancer cells. The results could help to explain why many cancer drugs fail in clinical trials, says William Kaelin.
Read more...